drugset / Trial / NCT06030193
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
Timeline
- Start
- 2025-08-13
- Primary completion
- 2026-02-23
- Completion
- 2026-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLS-111 | Unknown | 0.015 % | Other |
| Comparator | Timolol | Other / unclassified | 0.5 % | Other |